newsfilter
← Latest News
Business Wire·

Auna Announces 1Q26 Financial Results

  • Auna reported 1Q26 consolidated revenue of S/1,178 million, a 13% year-over-year increase on a reported basis & a 10% increase excluding foreign exchange.
  • Mexico revenue grew 15% year-over-year to S/279 million, driven by a 13% quarter-over-quarter increase in patient volumes & a 32% surge in oncology business.
  • Adjusted EBITDA decreased 2% year-over-year to S/217 million, resulting in an 18.4% margin, down 2.9 percentage points from the prior year period.
  • Operating cash flow increased 48% year-over-year, while free cash flow grew 2.6 times compared to the same period in 2025.
  • The leverage ratio remained stable at 3.7x, with management targeting a medium-term ratio below 3.0x.
  • Mexico's segment Adjusted EBITDA rose 19% sequentially despite a 14% year-over-year decline, attributed to service mix changes & higher SG&A expenses.
  • Peru's Adjusted EBITDA was impacted by delayed pharmacy rebates & revenue adjustments, though Oncosalud secured a new group policy for the judiciary.
  • Colombia achieved 14% local currency revenue growth & a 7% increase in Adjusted EBITDA, with PGP risk-sharing contracts now comprising 21% of total revenues.
  • Oncology Medical Loss Ratio (MLR) decreased 2.0 percentage points year-over-year to 49.6%.
  • Surgery volumes increased 4.4% year-over-year to 21,610, while hospitalization days rose 2.9% to 132,266.
  • Net income for the quarter was S/9 million, down from S/38 million in 1Q25, primarily due to non-cash foreign exchange losses on net finance costs.
  • Auna reaffirmed its full-year revenue & Adjusted EBITDA guidance, citing improving trends across all three markets.
  • Net finance costs increased to S/141 million, driven largely by a S/26 million non-cash foreign exchange loss related to Peruvian Sol hedging structures.